Skip to content
Boston Scientific
-
Boston Scientific re-enters neurovascular market with USD14.5B Penumbra deal
Penumbra shareholders will have the option to receive either USD374 in cash or 3.8721 Boston Scientific shares, with the transaction structured as approximately 73% cash and 27% stock.